User profiles for P. J. Svensson

Peter Svensson

Lund
Verified email at med.lu.se
Cited by 6465

Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based …

…, DM Witt, PO Vandvik, J Fish, MJ Kovacs, PJ Svensson… - Chest, 2012 - Elsevier
Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to …

…, M Carlsson, PJ Svensson - Proceedings of the …, 1993 - National Acad Sciences
Although patients with thromboembolic disease frequently have family histories of thrombosis,
well-defined defects such as inherited deficiencies of anticoagulant proteins are found …

[HTML][HTML] Resistance to activated protein C as a basis for venous thrombosis

PJ Svensson, B Dahlback - New England Journal of Medicine, 1994 - Mass Medical Soc
Background In three families with various forms of venous thrombosis, we observed an
apparently inherited poor response to the anticoagulant activated protein C (APC). The condition …

Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss–a possible evolutionary selection mechanism

PG Lindqvist, PJ Svensson… - Thrombosis and …, 1998 - thieme-connect.com
… Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously
unrecognized mechanism characterized by poor anticoagulant response to activated protein C: …

Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.

B Zöller, PJ Svensson, X He… - The Journal of clinical …, 1994 - Am Soc Clin Investig
… Carlsson, and PJ Svensson. 1993. Familial thrombophilia due to a previously unrecognized
mechanism characterized by poor anticoagulant response to activated protein C. …

Genetic risk factors for venous thromboembolism

B Zöller, PJ Svensson, B Dahlbäck… - Expert Review of …, 2020 - Taylor & Francis
Introduction Venous thromboembolism (VTE) is a complex disease that aggregates in
families. Both acquired and genetic risk factors are important. Proper recognition and …

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA

…, M Rosenqvist, N Eriksson, PJ Svensson - European heart …, 2011 - academic.oup.com
Aims In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be
weighed against the risk of bleeding. Time in therapeutic range (TTR) is an important tool to …

Activated protein C resistance (FV: Q506) and pregnancy

PG Lindqvist, PJ Svensson, K Maršál… - Thrombosis and …, 1999 - thieme-connect.com
Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous …
Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous …

Cardiovascular risk factors associated with venous thromboembolism

…, LH Kuller, A Rosengren, PJ Svensson… - JAMA …, 2019 - jamanetwork.com
Importance It is uncertain to what extent established cardiovascular risk factors are associated
with venous thromboembolism (VTE). Objective To estimate the associations of major …

Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage

E Zia, G Engström, PJ Svensson, B Norrving… - Stroke, 2009 - Am Heart Assoc
Background and Purpose— There are few studies on the prognosis after primary intracerebral
hemorrhages, and they reported big differences in mortality rates. Our aim was to …